Anthony D. Saleh, Ph.D.
Tishan has significant experience in the fields of structural and molecular biology. Throughout her graduate studies and industry career, she has worked to elucidate the biophysical underpinnings of a myriad of biological pathways. Her strong background in the application of analytical techniques has helped hone her expertise in the practice of determining structure-function relationships between clinically-relevant protein targets and small molecule compounds. Her desire to conduct clinically translatable research led her to miRecule, where she focuses on the conception and characterization of novel therapeutic assets across multiple disease programs.
Charles is a scientist with years of experience in molecular and cell biology models to investigate the driving cause of diseases including Alzheimer’s, Parkinson’s and cancer. During his PhD he worked to further elucidate the molecular mechanisms of melanoma metastasis and collaborated to validate a novel therapeutic that helps counteract melanoma metastasis. His diverse experience in the pre-clinical development of novel therapeutics serves as an excellent basis for the validation of our oligonucleotide therapeutics.
Ami Bessell is an immunology PhD candidate from Johns Hopkins University, with a focus in tumor immunotherapy. Her experience with T cell driven therapy is focused in cellular specific uptake for beneficial therapy. Her work at miRecule focuses primarily on characterizing the delivery and activity of miRecule’s therapeutic compounds.